The LDL number is alive!

Česká verzia

Authors: Richard Češka
Authors place of work: Centrum preventivní kardiologie, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in the journal: AtheroRev 2021; 6(2): 84-89
Category: Reviews

Summary

Cardiovascular diseases, in particular those resulting from atherosclerosis, are currently the leading cause of mortality worldwide. Various risk factors are responsible for the development of atherosclerosis, and with regard to prevention and treatment only those that can be influenced are relevant: smoking, arterial hypertension, type 2 diabetes mellitus, central obesity, metabolic syndrome and hyperlipoproteinemia and dyslipidemia. High levels of LDL-cholesterol present a particularly high risk, and therefore it is necessary to focus on early detection and treatment of patients with this anomaly. The current pharmacological armamentarium provides sufficient means for that, and these are still expanding, as evidenced by the study ORION with inclisiran.

Keywords:

type 2 diabetes mellitus – inclisiran – LDL-cholesterol – ORION study

Zdroje

1. Landmesser U, Chapman MJ, Michel Farnier M et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J 2017; 38(29): 2245–2255. Dostupné z DOI: .

2. Mach F, Baigent C, Catapano AL et al. [Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Authors/Task Force Members]. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111–188. Dostupné z DOI: .

3. Borén J, Chapman MJ, Krauss RM et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41(24): 2313–2330. Dostupné z DOI: .

4. Ference BA, Ginsberg HN, Ian Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38(32): 2459–2472. Dostupné z DOI: .

5. Catapano AL, Graham I, De Backer G, et al. ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2016; 37(39): 2999–3058. Dostupné z DOI: .

6. Nordestgaard BG, Chapman MJ, Humphries SE et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34(45): 3478–3490a. Dostupné z DOI: .

7. Khera AV, Won HH, Peloso GM et al. Diagnostic yield of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016; 67(22): 2578–2589. Dostupné z DOI: .

8. Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis 2015; 243(1): 257–259. Dostupné z DOI: .

9. Watts GF, Gidding S, A.S. Wierzbicki AS et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol 2014; 8(2): 148–172. Dostupné z DOI: .

10. Češka R et al. Familiární hypercholesterolémie. Triton: Praha 2015. ISBN 978–80–7387–843–6.

11. American Heart Association (2014). Why Cholesterol Matters. Dostupné z WWW: . [07–2015].

12. Halcox JP, Tubach F, Lopez-Garciaet E et al. Low Rates of Both Lipid- Lowering Therapy Use and Achievement of Low-Density Lipoprotein Cholesterol Targets in Individuals at High-Risk for Cardiovascular Disease across Europe. PLoS One 2015; 10(2): e0115270. Dostupné z DOI: .

13. Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563–1574. Dostupné z DOI: .

14. Watts GF, Ooi EM. Balancing the cardiometabolic benefits and risks of statins. Lancet 2012; 380(9841): 541–543. Dostupné z DOI: .

15. McGowan MP. Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol-- the role of LDL-apheresis. J Clin Lipidol 2013; 7(3 Suppl): S21-S26. Dostupné z DOI: .

16. Kastelein JJ, Wedel MK, Baker BF et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114(16): 1729–1735. Dostupné z DOI: .

17. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 (suppl): S172–S177. Dostupné z DOI: .

18. Jimenez JG, Rosen JB, Pirags V et al. The efﬁcacy and safety of ezetimibe/ simvastatin combination compared with intensiﬁed lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrom. Diabetes Obes Metab 2013; 15(6): 513–522. Dostupné z DOI: .

19. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670–1681. Dostupné z DOI: .

20. Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581–590. Dostupné z DOI: .

21. Taylor F, Huffman MD, Macedo AF et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1): CD004816. Dostupné z DOI: .

22. Christopher P, Cannon CP, Blazing MA et al. [IMPROVE-IT Investigators]. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387–2397. Dostupné z DOI: .

23. Anne B. Rossebø AB, Pedersen TR, Boman K et al. [SEAS Investigators]. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med 2008; 359(13): 1343–1356. Dostupné z DOI: .

24. Waters DD, Ho JE, Boekholdt SM et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013; 61(2): 148–152. Dostupné z DOI: .

25. Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Curr Atheroscler Rep 2016; 18(10): 61. Dostupné z DOI: .

26. Laufs U, Banach M, Mancini GB. Efficacy and Safety of Bempedoic Acid in Patients with Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc 2019; 8(7): e011662. Dostupné z DOI: http://dx.doi.org/10.1161/ JAHA.118.011662>.

27. Khan SU, Michos ED. Bempedoic acid and ezetimibe – better together. Eur J Prev Cardiol 2020; 27(6): 590–592. Dostupné z DOI: .

28. Ray KK, Wright RS, Kallend D et al. [ORION-10 and ORION-11 Investigators]. Two Phase 3 Trials of Inclisiran in Patients With Elevated LDL Cholesterol. N Engl J Med 2020; 382(16): 1507–1519. Dostupné z DOI: .

29. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251(3): 351– 364. Dostupné z DOI: .

30. [Scandinavian Simvastatin Survival Study Group]. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383– 1389. Dostupné z DOI: .